The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study (Retracted Article. See vol 96, pg 1021, 2005)
The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study (Retracted Article. See vol 96, pg 1021, 2005)
复制标题
DOI：
10.1016/j.ygyno.2004.06.048
复制
发表时间：
2004-10-01
影响因子：
4.7
通讯作者：
Pfisterer, J
中科院分区：
文献类型：
--
作者：
Riener, EK;Arnold, N;Pfisterer, J
Objective. HER-2/neu失调在上皮性卵巢癌中的预后和预测相关性是有争议的。本研究的目的是记录HER-2/neu的表达模式及其与临床病理参数和生存率的相关性。采用免疫组化法检测HER-2/neu在卵巢癌组织中的表达。免疫组化染色根据既定的协议进行。结果与临床数据。结果HER-2/neu过表达率为6.9%（25/361），与肿瘤分期密切相关（P=0.03），但没有淋巴结转移（P=0.5）、肿瘤分级（P=0.3）、组织学类型（P=0.6）、残余肿瘤（P=0.4）、治疗前血清CA-125（P=0.2）和患者年龄（P=0.8）。我们发现HER-2/neu过表达对总体和无病生存期没有显著影响，与FIGO分期、肿瘤分级和残留肿瘤质量无关。在73例次优减容患者的亚组中，对一线化疗有反应（完全缓解[CR] +部分缓解[PR]）和对一线化疗无反应（疾病稳定[SDI]+疾病进展[PD]）的女性HER-2/neu过表达率存在显著差异（0% [0/51] vs. 14% [3/22]; P=0.02）。HER-2/neu在晚期卵巢癌患者中的过度表达是罕见的，除了已确定的临床病理学参数外，没有提供预后信息。然而，这项多中心研究表明HER-2/neu过表达是次优减容患者对一线化疗反应的预测因素。(C)2004年爱思唯尔公司All rights reserved.
Objective. The prognostic and predictive relevance of HER-2/neu dysregulation in epithelia] ovarian cancer is controversial. The purpose of our study was to document HER-2/neu expression patterns and their correlation with clinicopathologic parameters and survival in a large and biologically homogenous Caucasian patient collective.Methods. Expression of HER-2/neu in ovarian cancer tissue was assessed by immunohistochemistry. Immunohistochemical staining was performed according to established protocols.Results were correlated to clinical data. Results. HER-2/neu overexpression was detected in 6.9% (25/361) of the tumor samples and was significantly associated with tumor stage (P=0.03), but not with lymph node involvement (P=0.5), tumor grade (P=0.3), histological type (P=0.6), residual tumor (P=0.4), serum CA-125 before therapy (P=0.2), and patient age (P=0.8). We found no significant influence of HER-2/neu overexpression on overall and disease-free survival independent of FIGO stage, tumor grade, and residual tumor mass. In a subset of 73 suboptimally debulked patients, women with response to first-line chemotherapy (complete remission [CR] + partial remission [PR]) and no response to first-line chemotherapy (stable disease [SDI + progressive disease [PD]) showed significantly different rates of HER-2/neu overexpression (0% [0/51] vs. 14% [3/22]; P=0.02).Conclusions. Tumor overexpression of HER-2/neu in women with advanced ovarian cancer is rare and provides no prognostic information in addition to that provided by established clinicopathologic parameters. This multicenter study, however, indicates that HER-2/neu overexpression is a predictive factor for the response to first-line chemotherapy in suboptimally debulked patients. (C) 2004 Elsevier Inc. All rights reserved.